Press Releases Press Releases Year None202420232022202120202019201820172016201520142013201120102009200820072005 December 11, 2024 Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting PDF Version December 3, 2024 Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy PDF Version November 19, 2024 Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences PDF Version November 7, 2024 Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress PDF Version November 5, 2024 Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia PDF Version October 30, 2024 Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance PDF Version October 17, 2024 Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast PDF Version September 23, 2024 Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress PDF Version August 28, 2024 Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences PDF Version August 8, 2024 Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
December 11, 2024 Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting PDF Version
December 3, 2024 Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy PDF Version
November 19, 2024 Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences PDF Version
November 7, 2024 Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress PDF Version
November 5, 2024 Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia PDF Version
October 30, 2024 Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance PDF Version
October 17, 2024 Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast PDF Version
September 23, 2024 Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress PDF Version
August 28, 2024 Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences PDF Version
August 8, 2024 Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference PDF Version
